New hope for hard-to-treat lymphoma: experimental combo targets relapsed patients

This study tests whether adding the experimental drug IMM0306 to standard lenalidomide helps people with relapsed or refractory follicular lymphoma achieve complete remission and live longer without the cancer worsening. About 198 adults who have already tried at least two prior treatments will be randomly assigned to receive either IMM0306 plus lenalidomide or a placebo plus lenalidomide. The trial is double-blind, meaning neither patients nor doctors know who gets the experimental drug.